Wednesday, December 14, 2005 :: EUROPEAN CANCER CENTER UNVEILS CT LASER MAMMOGRAPHY TECHNOLOGY
EUROPEAN CANCER CENTER UNVEILS CT LASER MAMMOGRAPHY TECHNOLOGY


Fort Lauderdale, Florida, December 14, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) reported that that the CT Laser Mammography (CTLM®) system was officially introduced to the Polish medical community and public at the opening ceremonies of the Center of Prophylactic and Early Cancer Diagnosis at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology on November 16th, 2005, in Gliwice, Poland.

Professor Boguslaw Maciejewski, MD, PhD, FACR, Director of the Institute of Oncology, began the day-long program with a press conference featuring a panel of oncology physicians and industry leaders. The panel stressed the capabilities of the Polish Institute of Oncology, especially the Gliwice Branch, which was recently updated with the latest innovations. Panel member Tim Hansen, IDSI Chief Executive Officer, spoke about the CTLM system’s advanced technologies. The interview was followed by a public grand opening conference and ceremony featuring the panel members.

Hosted tours of the Center highlighted many cutting-edge modalities. Several ribbon-cutting ceremonies unveiled advances in MRI imaging, radiation treatment planning, ultrasound, and CT Laser Mammography, among others.

“The Institute of Oncology is our premiere reference site in Europe, featuring two CTLM systems and a significant patient caseload,” commented Hansen. “They have completed over 1,500 laser mammography patient studies and serve over 7 million people in their region. Our partnership with the Institute enables us to explore routine diagnostic CTLM imaging as well as applications in oncology. Our research areas involve innovative studies, such as CTLM applicability to estimation of tumor regression rates and local tumor clearance, as well as correlations between CTLM and mammography images with molecular biomarkers. Through our collaboration, we are gaining valuable insights; we look forward to seeing the Center publish their findings.”

The ceremony and CTLM debut was broadcast on television and radio stations throughout Poland, along with interviews with Professor Maciejewski that discussed breast studies and new diagnostic and screening capabilities in the Gliwice region. An educational program on new techniques in breast imaging, highlighting the CTLM system, is also being developed, with the help of EDOMED, IDSI’s exclusive distributor in Poland. The 30-minute program is scheduled to air on December 22nd on Poland’s national television station, TVP1.

The Institute of Oncology, a Comprehensive Cancer Center, has been registered by the Organization of European Cancer Institutes (O.E.C.I.) as a European Comprehensive Cancer Centre of Excellence since 2002.


The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Thursday, December 8, 2005 :: CT LASER MAMMOGRAPHY RESULTS SHOWN AT MAJOR RADIOLOGICAL MEETING
CT LASER MAMMOGRAPHY RESULTS SHOWN AT MAJOR RADIOLOGICAL MEETING

Fort Lauderdale, Florida, December 8, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced good commercial and clinical response to international clinical results shown at RSNA 2005, the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America. RSNA is IDSI’s major event of the year, a forum in which to present clinical results, work-in-progress, and international commercial results to more than 60,000 attendees.

IDSI featured results from its exclusive CT Laser Mammography (CTLM®) scanner and highlighted its leadership in laser optical mammography technology by exhibiting select clinical cases from the more than 6,000 studies that have been completed worldwide.

“We presented cases from many of our luminary and partner sites which showed CTLM results in the context of complete cases worked up with mammography, ultrasound, breast MRI, and biopsy results,” explained Eric Milne, MD, FRCR, FRCP, IDSI Director of Clinical Research. “The comparisons were particularly useful to illustrate the adjunctive value of imaging the angiogenesis processes with passive CT laser technologies.”

Tim Hansen, IDSI Chief Executive Officer stated, “We were extremely pleased to have garnered such great interest in our revolutionary new modality and our approach to detecting and managing breast cancer. Our users presented compelling clinical results, our international distributors brought in attentive and interested prospects, and we received serious attention from university-level radiologists who are beginning to understand the key role CTLM may play in multimodality breast cancer case management.”

Commented Dr. Milne, “The acceptance of our non-invasive optical method of detecting angiogenesis in breast cancer, which we have been developing and promulgating for close to ten years, has been confirmed at this year’s RSNA meeting by the virtual ‘explosion’ in technical developments of MRI of the breast, designed to image angiogenesis, and in the many papers presented on angiogenesis in breast cancer.”

IDSI also received international media attention, providing interviews to German and American publications as well as Australian television.

The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, November 8, 2005 :: IMAGING DIAGNOSTIC SYSTEMS HIGHLIGHTS NEW CLINICAL RESULTS AT RSNA 2005
IMAGING DIAGNOSTIC SYSTEMS HIGHLIGHTS NEW CLINICAL RESULTS AT RSNA 2005


Fort Lauderdale, Florida, November 8, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced that IDSI will display new clinical results and feature the CT Laser Mammography System at RSNA 2005, November 27 – December 2, in Chicago, Illinois. IDSI will be located at Booth #5139 in the South Hall.

“We have made impressive clinical progress since last year’s RSNA,” stated Tim Hansen, IDSI Chief Executive Officer. “Earlier this year, our first peer-reviewed CT Laser Mammography paper was published. Our exam volume has risen to over 6,000 as a result of the efforts of our international users and our research partners. Many of these new clinical cases will be presented at this important global imaging venue. Our results underscore our extensive experience and leadership in laser optical breast imaging. We are looking forward to sharing these developments with breast and molecular imaging specialists.”

RSNA 2005 is the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America. A forum for radiologic science and technology, RSNA features scientific papers, posters, courses, lectures, symposia, and exhibits. In 2004, the annual meeting attracted over 60,000 attendees.

The CT Laser Mammography (CTLMâ) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Monday, November 7, 2005 :: IDSI ADVANCED DEVELOPMENT DIRECTOR INVITED TO JOIN FLORIDA INTERNATIONAL UNIVERSITY BIOMEDICAL ENGINEERING ADVISORY BOARD
IDSI ADVANCED DEVELOPMENT DIRECTOR INVITED TO JOIN FLORIDA INTERNATIONAL UNIVERSITY BIOMEDICAL ENGINEERING ADVISORY BOARD

Fort Lauderdale, Florida, November 7th, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that Steven Ponder, Ph.D., IDSI Director, Advanced Development, has been invited to join Florida International University (FIU)’s Biomedical Engineering Partnership Program (BMEPP) Advisory Board. Ponder will represent IDSI on the board, which integrates academia, clinical medicine, and the biomedical industry.

“We are very pleased to have Imaging Diagnostic Systems and Steven Ponder as part of the Advisory Board,” stated Ofer Amit, Biomedical Engineering Partnership Program Director. “The work that IDSI is doing with laser molecular imaging and CT technology places them among the biomedical engineering leaders in South Florida and the nation that comprise our program.”

The advisory board serves as a liaison between FIU’s Department of Biomedical Engineering, biomedical corporations, and the clinical community, providing a forum for the exchange of knowledge, networking, and establishment of joint projects. The Biomedical Engineering Advisory Board is comprised of representatives from prominent hospitals, research centers, and biomedical industry leaders such as Mount Sinai, Cordis, Bioheart, Boston Scientific, and Beckman-Coulter.

“We are pleased to have this opportunity to cooperate with the local academic community and to support the education of the next generation of biomedical engineers,” Ponder stated. “I look forward to a fruitful collaboration between Imaging Diagnostic Systems and Florida International University.”

The next meeting of the Advisory Board will be held on November 23rd.

The CTLMâ system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com